Caspase inhibitors as neuroprotective agents

Bibliography

• ROBERTSON GS, CROCKER SJ, NICHOLSON DW, SCHULZ JB: Neuroprotection by the inhibition of apoptosis. Brain Pathol. (2000) 10:283.
   PubMed Web of Science ®Google Scholar
• SCHULZ JB, WELLER M, MOSKOWITZ MA: Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol (1999) 45:421.
   PubMed Web of Science ®Google Scholar
• ••Good review article covering the biology of caspases in CNSinjury/disease.
   Google Scholar
• VILLA P, KAUFMANN SH, EARNSHAW WC: Caspases and caspase inhibitors. Trends Biochem. Sci. (1997) 22:388.
   PubMed Web of Science ®Google Scholar
• WELLINGTON CL, HAYDEN MR: Caspases and neurode-generation: on the cutting edge of new therapeutic approaches. Clin. Genetics (2000) 57:1.
   PubMed Web of Science ®Google Scholar
• PARSONS AA, IRVING EA, LEGOS JJ, et al.: Acute stroketherapy: translating preclinical neuroprotection to therapeutic reality. Curr. Opin. Invest. Drugs (2000) 1:452.
   PubMedGoogle Scholar
• •Review summarising our recent advances in the understanding of focal stroke and a discussion of the various confounding factors that should be addressed in developing novel therapeutics.
   Google Scholar
• BULLOCK MR, LYETH BG, MUIZELAAR JP: Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery (1999) 45:207.
   PubMed Web of Science ®Google Scholar
• •Summary of the potential factors that may contribute to the discrepancies between animal models and human clinical trials and a set of recommendations to avoid future pitfalls.
   Google Scholar
• STEPHENSON J: Rising stroke rates spur efforts to identify risks, prevent disease. JAMA (1998) 279:1239.
   PubMed Web of Science ®Google Scholar
• FISHER M, BOGOUSSLAVAVSKY J: Further evolution toward effective therapy for acute ischemic stroke. JAMA (1998) 279:1298.
   PubMed Web of Science ®Google Scholar
• BARONE FC: Emerging therapeutic targets in focal stroke and brain trauma: cytokines and the brain inflammatory response to injury. Emerg. Ther. Targets (1998) 2:2.
   Google Scholar
• MARION DW: Head and spinal cord injury. Neurologic Clin. (1998) 16:485.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ PA, YOUNG RR, VULPE M: Spinal cord injury. An overview. Urologic Clin. N Am. (1993) 20:373.
   PubMed Web of Science ®Google Scholar
• MCNAIR ND: Traumatic brain injury. Nursing Clin. N Am. (1999) 34:637.
   PubMed Web of Science ®Google Scholar
• YOUNG W, BRACKEN MB: The Second National Acute Spinal Cord Injury Study. J. Neurotrauma (1992) 9:S397.
   PubMed Web of Science ®Google Scholar
• BRACKEN MB, SHEPARD MJ, HELLENBRAND KG, et al: Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurgery (1985) 63: 704.
   Google Scholar
• BRACKEN MB, SHEPARD MJ, COLLINS WF, et al: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study [see comments]. N Engl. J. Med. (1990) 322:1405.
   PubMed Web of Science ®Google Scholar
• BRACKEN MB, SHEPARD MJ, HOLFORD TR, et al.: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA (1997) 277:1597.
   PubMed Web of Science ®Google Scholar
• BRACKEN MB, SHEPARD MJ, HOLFORD TR, et al.: Methyl-prednisolon e or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury random-ized controlled trial. J. Neurosurgery (1998) 89:699.
   PubMed Web of Science ®Google Scholar
• CONSTANTINI S, YOUNG W: The effects of methyl-prednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J. Neurosurgery (1994) 80:97.
   PubMed Web of Science ®Google Scholar
• GALANDIUK S, RAQUE G, APPEL S, POLK HC, Jr.: The two-edged sword of large-dose steroids for spinal cord trauma. Ann. Surgery (1993) 218:419.
   PubMed Web of Science ®Google Scholar
• GERNDT SJ, RODRIGUEZ JL, PAWLIK JW, et al.: Consequences of high-dose steroid therapy for acute spinal cord injury. J. Trauma-Injury Infect. Grit. Care (1997) 42:279.
   PubMed Web of Science ®Google Scholar
• SHORT DJ, EL MASRY WS, JONES PW: High dose methyl-prednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspec-tive. Spinal Cord (2000) 3 8 :273.
   Google Scholar
• SCHIERHOUT G, ROBERTS I: Mannitol for acutetraumatic brain injury. Cochrane Database of Systematic Reviews (2000) [computer file]:CD001049.
   Google Scholar
• PANCIOLI AM, BORDERICK J, KOTHARI R, et al.: Publicperception of stroke warning signs and knowledge of potential risk factors. JAMA (1998) 279:1288.
   PubMed Web of Science ®Google Scholar
• FADEEL B, ORRENIUS S, ZHIVOTOVSKY B: The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia (2000) 14: 1514.
   PubMed Web of Science ®Google Scholar
• THORNBERRY NA, LAZEBNIK Y: Caspases: enemies within. Science (1998) 281:1312.
   PubMed Web of Science ®Google Scholar
• YUAN J, SHAHAM S, LEDOUX S, ELLIS HM, HORVITZ HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell (1993) 75:641.
   PubMed Web of Science ®Google Scholar
• THORNBERRY NA, RANO TA, PETERSON EP, et al.: A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol. Chem. (1997) 272:17907.
   PubMed Web of Science ®Google Scholar
• TALANIAN RV, QUINLAN C, TRAUTZ S, et al.: Substratespecificities of caspase family proteases. J. Biol. Chem. (1997) 272:9677.
   PubMed Web of Science ®Google Scholar
• FANTUZZI G, DINARELLO CA: Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). j Clin. Immunol. (1999) 19:1.
   PubMed Web of Science ®Google Scholar
• BARONE FC, PARSONS AA: Therapeutic potential of anti-inflammatory drugs in focal stroke. Exp. Opin. Invest. Drugs (2000) 9:2281.
   PubMed Web of Science ®Google Scholar
• •Good review of inflammatory mechanisms in stroke, particularly in relation to IL-1I3.
   Google Scholar
• GRAHAM DI, MCINTOSH TK, MAXWELL WL, NICOLL JA: Recent advances in neurotrauma. J. Neuropathol. Exp. Neurol. (2000) 59:641.
   PubMed Web of Science ®Google Scholar
• •Update on the pathophysiology of CNS traumas.
   Google Scholar
• KERMER P, KLOCKER N, BAHR M: Neuronal death after brain injury. Models, mechanisms and therapeutic strategies in vivo. Cell Tissue Res. (1999) 298:383.
   PubMed Web of Science ®Google Scholar
• LU J, ASHVVELL KW, WAITE P: Advances in secondary spinal cord injury: role of apoptosis. Spine (2000) 25:1859.
   PubMed Web of Science ®Google Scholar
• CLARK RS, KOCHANEK PM, CHEN M, et al.: Increases inBc1-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. FASEB (1999) 13:813.
   PubMed Web of Science ®Google Scholar
• •Evidence from human tissue of apoptotic mechanisms following TBI.
   Google Scholar
• YAKOVLEV AG, KNOBLACH SM, FAN L, FOX GB, GOODNIGHT R, FADEN Al: Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. Neurosci. (1997) 17:7415.
   PubMed Web of Science ®Google Scholar
• BEER R, FRANZ G, SRINIVASAN A, et al: Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem. (2000) 75:1264.
   PubMed Web of Science ®Google Scholar
• CLARK RS, KOCHANEK PM, WATKINS SC, et al.: Gasp ase-3 mediated neuronal death after traumatic brain injury in rats. J. Neurochem. (2000) 74:740.
   PubMed Web of Science ®Google Scholar
• BUKI A, OKONKWO DO, WANG KK, POVLISHOCK JT: Cytochrome c release and caspase activation in traumatic axonal injury. J NeuroscL (2000) 20:2825.
   PubMed Web of Science ®Google Scholar
• FINK KB, ANDREWS LJ, BUTLER WE, et al: Reduction of post-traumatic brain injury and free radical produc-tion by inhibition of the caspase-1 cascade. Neurosci-ence (1999) 94:1213.
   PubMed Web of Science ®Google Scholar
• CROWE MJ, BRESNAHAN JC, SHUMAN SL, MASTERS JN, BEATTIE MS: Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys [published erratum appears in Nature Med. (1997) 3(2):240]. Nature Med. (1997) 3:73.
   PubMed Web of Science ®Google Scholar
• •Demonstrates delayed cell death in remote regions from injury site over several months.
   Google Scholar
• EMERY E, ALDANA P, BUNGE MB, et al.: Apoptosis after traumatic human spinal cord injury. J. Neurosurg. (1998) 89:911.
   PubMed Web of Science ®Google Scholar
• •Only study in humans demonstrating potential role for apoptosis following SCI.
   Google Scholar
• LI M, ONA VO, CHEN M, et al: Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury. Neuroscience (2000) 99:333.
   PubMed Web of Science ®Google Scholar
• SPRINGER JE, AZBILL RD, KNAPP PE: Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nature Med. (1999) 5:943.
   PubMed Web of Science ®Google Scholar
• VELIER JJ, ELLISON JA, KIKLY KK, SPERA PA, BARONE FC, FEUERSTEIN GZ: Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat. J. NeuroscL (1999) 19:5932.
   PubMed Web of Science ®Google Scholar
• FINK K, ZHU J, NAMURA S, et al.: Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J. Cerebral Blood Flow Metab. (1998) 18:1071.
   PubMed Web of Science ®Google Scholar
• •Experimental model suggesting that there may be an extended window for treatment with caspase inhibitors.
   Google Scholar
• NAMURA S, ZHU JM, FINK K, et al.: Activation and cleavage of caspase-3 in apoptosis induced by experi-mental cerebral ischemia. j Neurosci. (1998) 18: 3659.
   PubMed Web of Science ®Google Scholar
• OUYANG YB, TAN Y, COMB M, et al.: Survival- anddeath-promoting events after transient cerebral ischemia: phosphorylation of Akt, release of cytochrome c and Activation of caspase-like proteases. J. Cerebral Blood Flow Metab. (1999) 19:1126.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER RM, GAGLIARDINI V, HARA H, et al.:Expression of a dominant negative mutant of interleukin-1-beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp. Med. (1997) 185:933.
   PubMed Web of Science ®Google Scholar
• MINAMI M, KURAISHI Y, YABUUCHI K, YAMAZAKI A, SATOH M: Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. j Neurochem. (1992) 58:390.
   PubMed Web of Science ®Google Scholar
• LIU T, MCDONNELL PC, YOUNG PR, et al.: Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke (1993) 24:1746.
   PubMed Web of Science ®Google Scholar
• LEGOS JJ, WHITMORE RG, ERHARDT JA, PARSONS AA, TUMA RF, BARONE FC: Quantitative changes in interleukin proteins following focal stroke in the rat. NeuroscL Letts. (2000) 282:189.
   PubMed Web of Science ®Google Scholar
• RELTON JK, ROTHWELL NJ: Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. (1992) 29:243.
   PubMed Web of Science ®Google Scholar
• ROTHWELL NJ, RELTON JK: Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc. Brain Metab. Rev. (1993) 5:178.
   PubMedGoogle Scholar
• MARTIN D, CHINOOKOSWONG N, MILLER G: The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hyp oxia-ischemia. Exp. Neurol (1994) 130:362.
   PubMed Web of Science ®Google Scholar
• TOULMOND S, ROTHWELL NJ: Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. (1995) 67:261.
   Google Scholar
• BETZ AL, YANG GY, DAVIDSON BL: Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cerebral Blood Flow Metab. (1995) 15:547.
   PubMed Web of Science ®Google Scholar
• RELTON JK, MARTIN D, THOMPSON RC, RUSSELL DA: Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol (1996) 138: 206.
   PubMed Web of Science ®Google Scholar
• SCHIELKE GP, YANG GY, SHIVERS BD, BETZ AL: Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J. Cerebral Blood Flow Metab. (1998) 18:180.
   PubMed Web of Science ®Google Scholar
• XU DG, CROCKER SJ, DOUCET JP, et al.: Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nature Med. (1997) 3:997.
   PubMed Web of Science ®Google Scholar
• RABUFFETTI M, SCIORATI C, TAROZZO G, CLEMENTI E,MANFREDI AA, BELTRAMO M: Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. j NeuroscL (2000) 20:4398.
   PubMed Web of Science ®Google Scholar
• •Study suggests the possibility that improved outcome following treatment with a caspase-1 inhibitor in experimental ischaemia may result from inhibition of apoptosis and/or inhibition of the inflammatory response.
   Google Scholar
• HARA H, FRIEDLANDER RM, GAGLIARDINI V, et al: Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA (1997) 94:2007.
   PubMed Web of Science ®Google Scholar
• ••Study utilises several available peptide inhibitors in experi-mental ischemic injury, and examines both neuroprotective and behavioral effects.
   Google Scholar
• ENDRES H, NAMURA S, SKIMIZUSASAMATA M, et al: Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb. Blood Flow Metab. (1998) 18:238.
   PubMed Web of Science ®Google Scholar
• WIESSNER C, SAUER D, ALAIMO D, ALLEGRINI PR: Protec-tive effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell. Mol. Biol. (2000) 46: 53.
   PubMed Web of Science ®Google Scholar
• LODDICK SA, MACKENZIE A, ROTHWELL NJ: An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. NeuroReport (1996) 7:1465.
   PubMed Web of Science ®Google Scholar
• LEE D, LONG SA, ADAMS JL, et al.: Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit ap op to sis and maintain cell functionality. J Biol. Chem. (2000) 275:16007.
   PubMed Web of Science ®Google Scholar
• •First full publication on non-peptide caspase inhibitors.
   Google Scholar
• NUTTALL M, LEE D, MCLAUGHLIN B, ERHARDT JA: Selective inhibitors of apoptotic cascades: implica-tions for novel therapeutic strategies. Drug Disc. Today (2001) 6:85.
   PubMed Web of Science ®Google Scholar
• ERHARDT J, LEGOS JJ, WONG VY, et al.: Critical role for caspase-3/-7 in PC12 cell death following trophic factor deprivation established through use of novel caspase inhibitor. Soc. Neurosci. Abstracts (2000) 26:604.
   Google Scholar
• GASPO R, ROBERTSON GS, WANHILL R, et al.: A caspase-3 selective inhibitor, L-826,791 reduces brain injury without altering limbic seizure activity mediated by kain ate-inducedex cito toxicity. Soc. Neurosci. Abstracts (2000) 26.
   Google Scholar
• CYTOVIA I: Caspase inhibitors for the treatment of acute, life-threatening degenerative diseases. Company Communication (1999)4.
   Google Scholar
• CATS WANG Y, HUANG J, et al: CV-1013, a novel, potent and irreversible pan-caspase inhibitor with activity in animal models of hepatitis, stroke and myocardial infarction. Am. Chem. Soc. (2000) 220:153.
   Google Scholar
• DECKWERTH T, ADAMS LM, WIESSNER C, et al.: Pep tidomimetic caspase inhibitors with neuroprotec-tive activity in vitro and in vivo. Soc. Neurosci. Abstracts (2000) 26.
   Google Scholar
• SAYERS R, WONG AM, SRINIVASAN A, et al.: Role of inhibition of caspase activity, processing and caspase substrate cleavage in the survival of apoptotic cortical and sympathetic neurons by the caspase inhibitor IDN5370 (CGP82630). Soc. Neurosci. Abstracts (2000) 26.
   Google Scholar
• BULLOCK MR, MERCHANT RE, CARMACK CA, et al.: An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. NY Acad. Sci. (1999) 890:51.
   PubMed Web of Science ®Google Scholar
• MERCHANT RE, BULLOCK MR, CARMACK CA, et al.: A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. NY Acad. Sci. (1999) 890:42.
   PubMed Web of Science ®Google Scholar
• SHIBATA M, HISAHARA S, HARA H, et al.: Caspases determine the vulnerability of oligodendrocytes in the ischemic brain. J Clin. Invest. (2000) 106:643.
   Google Scholar
• MA J, ENDRES M, MOSKOWITZ MA: Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice. Br. J Pharmacol. (1998) 124:756.
   PubMed Web of Science ®Google Scholar
• GILLARDON F, KIPRIANOVA I, SANDKUHLER J, HOSSMAN KA, SPRANGER M: Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentia-tion following global ischemia. Neuroscience (1999) 93:1219.
   PubMed Web of Science ®Google Scholar
• SCHOTTE P, DECLERCQ W, VAN HUFFEL S, VANDENA-BEELE P, BEYAERT R: Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett. (1999) 442:117.
   PubMed Web of Science ®Google Scholar
• •Implication that available tool compounds are non-selective with regard to other proteases.
   Google Scholar
• VANCOMPERNOLLE K, VAN HERREWEGHE F, PYNAERT G, et al: Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett. (1998) 438:150.
   PubMed Web of Science ®Google Scholar
• YAMASHIMA T: Implication of cysteine proteases calpain, cathep sin and caspase in ischemic neuronal death of primates. Prog. Neurobiol. (2000) 62:273.
   PubMed Web of Science ®Google Scholar
• Z PASINELLI P, HOUSEWEART MK, BROWN RH, CLEVELAND DW: Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc. Nati Acad. Sci. USA (2000) 97:13901.
   PubMed Web of Science ®Google Scholar
• M LI, ONA MW, GUEGAN VO, et al.: Functional role ofcaspase-1 and caspase-3 in an ALS transgenic mouse model. Science (2000) 288:335.
   PubMed Web of Science ®Google Scholar
• EBERHARDT O, COELLN RV, KUGLER S, et al: Protectionby synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1 -methyl-4-phenyl-1,2,3,6-tetr ahydr opyridine model of Parkinson's disease. J. Neurosci. (2000) 20:9126.
   PubMed Web of Science ®Google Scholar
• TATTON NA: Increased caspase 3 and Bax immunore-activity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. (2000) 166:29.
   PubMed Web of Science ®Google Scholar
• DA COSTA CA, ANCOLIO K, CHECLER F: Wild-type but not Parkinson's disease-related Ala-53 - > Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. (2000) 275:24065.
   PubMed Web of Science ®Google Scholar
• MOGI M, TOGARI A, KONDO T, et al.: Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. J. Neural Trans. (2000) 107:335.
   PubMed Web of Science ®Google Scholar
• HARTMANN A, HUNOT S, MICHEL PP, et al: Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. ScL USA (2000) 97:2875.
   PubMed Web of Science ®Google Scholar
• FEINKLESTEIN SP, FISHER M, FURLAND AJ, et al.: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 30:2752.
   PubMed Web of Science ®Google Scholar
• •Summary of a conference of academics and industry representatives to provide overall guidelines for the development of neuroprotective drugs.
   Google Scholar